Pembrolizumab is now approved

Pembrolizumab is now approved for first line treatment - Hallwang Clinic - Private Oncology Clinic on Facebook

Pembrolizumab is now also approved for first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma.



FDA Approves Pembrolizumab for the First-Line Treatment of Head and Neck Squamous Cell Carcinoma

Leave a Reply

Your email address will not be published. Required fields are marked *